[Review] Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions

RegulatoryapprovedDaratumumabCyclophosphamideBortezomibPositive

AI Analysis

Summary

A review article highlights treatment advancements in systemic amyloidosis, noting that six novel therapies have been approved for transthyretin (ATTR) amyloidosis since 2018 and a combination regimen was approved for light chain (AL) amyloidosis in 2021, transforming previously fatal orphan diseases into highly treatable conditions.

Outcome Details

Six novel therapies approved for ATTR amyloidosis since 2018; daratumumab-cyclophosphamide-bortezomib-dexamethasone combination approved for AL amyloidosis in 2021

Importance:4/10

Sentiment:

0.80

amyloidosisrare diseaseFDA approvalATTRAL amyloidosisorphan disease

Related Companies

$FVNNU $DMII

Read the original article

Published by The Lancet on July 8, 2026 10:30 PM

Read Original